APA (7th ed.) Citation

Atreya, R., Ferrante, M., Panaccione, R., Feagan, B., Shchukina, O., Jairath, V., . . . D'Haens, G. (2025). Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. Journal of Crohn's & Colitis, 19(4), 1. https://doi.org/10.1093/ecco-jcc/jjae164

Chicago Style (17th ed.) Citation

Atreya, Raja, et al. "Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies." Journal of Crohn's & Colitis 19, no. 4 (2025): 1. https://doi.org/10.1093/ecco-jcc/jjae164.

MLA (9th ed.) Citation

Atreya, Raja, et al. "Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies." Journal of Crohn's & Colitis, vol. 19, no. 4, 2025, p. 1, https://doi.org/10.1093/ecco-jcc/jjae164.